Antipsychotic Roundup 2009 (March)

Date of Issue: 03/01/2009 | Volume: 7 | Number: 3

Issue Links:Learning Objectives | Editorial Information

Teaser to be posted soon.

In This Issue


Atypicals for Non-psychotic disorders

You may have noticed a recent torrent of FDA approvals and clinical trials for atypical antipsychotics in every disorder under the sun–except psychosis. Is this simply an effort by the sponsoring companies to get us to prescribe more antipsychotics? Or are these drugs truly effective for non-psychotic disorders? What’s the quality of the evidence?

Read More

Prescribing Atypical Antipsychotics: What are the Risks?

Topics: Antipsychotics

Over the past several years, the use of antipsychotics has expanded dramatically. Aside from the traditional indication, schizophrenia, various members of this class have received FDA approval for bipolar mania, bipolar depression, major depression, and autism, and increasingly they are used off-label for anxiety, insomnia, and agitation.

Read More
Research Update

Two New Meta-Analyses Compare Antidepressants

Topics: Antidepressants

Two recent meta-analyses compared second-generation antidepressants (SGADs) to each other regarding efficacy and safety.

Read More
Expert QA

The Neurobiology of Schizophrenia

Dr. Jarskog, for many years the dopamine theory of schizophrenia has been dominant in the field. What is the current status of that theory?

Read More